NOD.CB17-PrkdcscidIl2rgtm1BcgenB2mtm2(B2M/HLA-A2.1)Bcgen/Bcgen • 112865
| Product name | huHSC-B-NDG HLA-A2.1 mice |
|---|---|
| Catalog number | 112865 |
| Strain name | NOD.CB17-PrkdcscidIl2rgtm1BcgenB2mtm2(B2M/HLA-A2.1)Bcgen/Bcgen |
| Strain background | B-NDG |
| Aliases | B2m: Ly-m11, beta2-m, beta2m; HLA-A: HLAA |
| Application | To verify the efficacy of HLA-A2.1 restricted vaccines；Promote the development of human CD8+ T cells |
Human CD34+ HSCs engraftment
Human CD34+ HSCs were successfully engrafted in B-NDG HLA-A2.1 mice. Human CD34+ HSCs were respectively engrafted in new born mice of B-NDG HLA-A2.1 mice and B-NDG mice after radiated with 0.8 Gy. (A) B-NDG HLA-A2.1 mice showed slightly lower survival rate than B-NDG mice, but no statistically significant difference. (B) Body weight.
Human CD34+ HSCs were successfully engrafted in B-NDG HLA-A2.1 mice. Human CD34+ HSCs were respectively engrafted in new born mice of B-NDG HLA-A2.1 mice and B-NDG mice after radiated with 0.8 Gy. Human leukocytes were analyzed by flow cytometry. Results showed that although the proportion of hCD8 + T cells in B-NDG HLA-A2.1 mice was significantly lower than that in B-NDG mice, it remains sustained at around 18% within 24 weeks of reconstitution. The proportion of hCD4 + T cells in B-NDG HLA-A2.1 mice was significantly higher than that in B-NDG mice. Proportions of other reconstituted cell types in B-NDG HLA-A2.1 mice were similar to that in B-NDG mice.
